Advertisement Sidebar
Recent Posts
- NATERA GALAXY Study Links ctDNA Status to Survival & Treatment Response ESMO 2024
- FDA approves KEYTRUDA® / Pembrolizumab with Chemotherapy for Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma SLIDES
- SLIDES: FDA Approves Kisqali / Ribociclib for Early High-Risk Breast Cancer
- VIDEO: iTeos and GSK’s TIGIT Combination Therapy Shows Significant Promise at ESMO 2024
- VIDEO: FDA Approves Atezolizumab / Tecentriq Hybreza For Subcutaneous PD-(L)1 Cancer Immunotherapy in NSCLC
Oncology Conference Videos
Oncology News
By. Ruth O’Regan MD Date: 12/07/2023In an interview, Ruth O’Regan MD addresses questions related to the…
Allen Wilbanks finds himself at SABCS 2023, where he engages in a discussion with Dr.…
By. Saranya Chumsri, MD Date: 12/12/2023 Saranya Chumsri, MD, an expert in the field of…
By. Ash Alizadeh, MD Date: 12/13/2023 At ASH 2023, Dr. Ash Alizadeh, a distinguished medical…
In an ongoing Phase 1/2 study, Constantine Tam, MD, a researcher and Professor of Haematology,…
Zandra Klippel, MD, Global Product Head, Sanofi – Phase 3 IsKia trial of Sarclisa® (isatuximab)…
At ASH 2023, Ola Landgren, MD, Professor of Medicine and Chief Division of Myeloma at…
Wassim Mchayleh, MD, a speaker at the Medical Data and Analysis Symposium (MDAS), discusses the…
In this ASH 2023 interview, Dr. Jos Melenhorst discusses a collaborative study on single-cell multi-omics…
Amidst the atmosphere of SABCS 2023, and at the center was Yara Abdou, MD, a…
Introduction to Myelofibrosis and JAK Inhibitors Myelofibrosis, a complex myeloproliferative neoplasm, presents a unique set…